EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors | Synapse
April 23, 2020Open Access
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
Key Points
Key points are not available for this paper at this time.
Abstract
These statements provide guidance on diagnosis and management of rheumatic irAEs and aim to support future international collaborations.